Wheeler Bio, an Oklahoma City, OK-based contract development and manufacturing organization (CDMO), raised an undisclosed amount in Series A funding.
The round was led by Charles River Laboratories and Echo Investment Capital with participation from ATUM, Floating Point Advisors, Plains Venture Partners, and Pine Ridge Ventures.
The company intends to use the funds to expand its drug substance GMP manufacturing facility in the Ziggurat building in Oklahoma City.
Led by CEO Jesse McCool, Wheeler Bio is a biomanufacturing company whose technology platform, Portable CMC™, simplifies the path between drug discovery and clinical manufacturing by standardizing the innovation-to-impact process.
Through key strategic partnerships with recognized CRO providers, like Alloy Therapeutics and ATUM, the company will continue building an innovative hub-and-spoke business model that connects biologics discovery technologies with an agile, open-source biomanufacturing platform for GMP clinical trial material.
FinSMEs
04/10/2022